Vector Labs Ab00449-1.4 Anti-alpha 5 beta 1 Integrin [M200 (Volociximab)], Mouse IgG1, Fc Silent™, kappa (200 μg) Centrifuge Bundle Savings at Sycamore Life Sciences

Description

Product Class: Purified
Clone ID: M200 (Volociximab)
Heavy Chain Modification: Fc Silent™
Synonyms: Fibronectin receptor; CD49 antigen-like family member E; Integrin alpha-F; VLA-5; CD49e.
Amount: 200 μg
Application Codes Clone: ELISA; FC; IF; Block; IHC-F; IHC-P
Shipping Temperature: Wet Ice
Buffer Composition: PBS with 0.02% Proclin 300.
Original Format: IgG4
Storage Temperature: Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Chimeric Use Statement: NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques.
Specificity Statement: This antibody is specific for human α5β1 integrin. Cross-reactivity studies revealed no binding to other human integrins such as α3β1, αvβ3, or αvβ5. It does, however, bind to α5β1 in the vasculature of cynomolgus monkeys, but not in mice. α5β1 is part of the integrin superfamily—glycoprotein transmembrane receptors that interact with ligands such as fibronectin, vitronectin, laminins, and collagens. This receptor plays a key role in processes including inflammation, cell proliferation, angiogenesis, and tumor metastasis.
Application Notes: This antibody binds human α5β1 integrin with high affinity (Kd = 0.367 nM, EC₅₀ = 0.2 nM, IC₅₀ = 2.3 nM) and, in chimeric mouse–human IgG4 form, demonstrated potent anti angiogenic and anti tumor effects in preclinical models (laser induced CNV in cynomolgus monkeys, VX2 carcinoma in rabbits) before progressing into Phase II trials in platinum resistant ovarian cancer (Ramakrishnan et al., 2006, PMID: 17024968; Bhaskar et al., 2007, PMID: 17786386). Exclusive binding to α5β1 (no cross reactivity with α3β1, αvβ3, αvβ5) was confirmed by ELISA. Immunohistochemistry (IHC-F) demonstrated binding to cynomolgus vasculature but not to mouse tissue. Studies with recombinant integrin subunits revealed that binding depends specifically on the human α5 chain, while the β1 chain can be of either human or mouse origin, indicating strict specificity for the α5β1 heterodimer (Bukowski et al., 2009; DOI: 10.1007/978-1-59745-332-5). In clinical testing, weekly 15 mg/kg IV dosing achieved trough serum levels >150 µg/mL, with 2–3× accumulation by Day 50, detectable antibody in ascites, reduction in circulating endothelial progenitor cells, and a favorable safety profile. The use of this antibody in IHC-P was demostrated (Bell McGuinn et al., 2011; PMID: 21276608). Clone F200, a Fab derivative of M200, is available upon request.

Product Class:	Purified
Clone ID:	M200 (Volociximab)
Heavy Chain Modification:	Fc Silent™
Synonyms:	Fibronectin receptor; CD49 antigen-like family member E; Integrin alpha-F; VLA-5; CD49e.
Amount:	200 μg
Application Codes Clone:	ELISA; FC; IF; Block; IHC-F; IHC-P
Shipping Temperature:	Wet Ice
Buffer Composition:	PBS with 0.02% Proclin 300.
Original Format:	IgG4
Storage Temperature:	Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Chimeric Use Statement:	NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques.
Specificity Statement:	This antibody is specific for human α5β1 integrin. Cross-reactivity studies revealed no binding to other human integrins such as α3β1, αvβ3, or αvβ5. It does, however, bind to α5β1 in the vasculature of cynomolgus monkeys, but not in mice. α5β1 is part of the integrin superfamily—glycoprotein transmembrane receptors that interact with ligands such as fibronectin, vitronectin, laminins, and collagens. This receptor plays a key role in processes including inflammation, cell proliferation, angiogenesis, and tumor metastasis.
Application Notes:	This antibody binds human α5β1 integrin with high affinity (Kd = 0.367 nM, EC₅₀ = 0.2 nM, IC₅₀ = 2.3 nM) and, in chimeric mouse–human IgG4 form, demonstrated potent anti angiogenic and anti tumor effects in preclinical models (laser induced CNV in cynomolgus monkeys, VX2 carcinoma in rabbits) before progressing into Phase II trials in platinum resistant ovarian cancer (Ramakrishnan et al., 2006, PMID: 17024968; Bhaskar et al., 2007, PMID: 17786386). Exclusive binding to α5β1 (no cross reactivity with α3β1, αvβ3, αvβ5) was confirmed by ELISA. Immunohistochemistry (IHC-F) demonstrated binding to cynomolgus vasculature but not to mouse tissue. Studies with recombinant integrin subunits revealed that binding depends specifically on the human α5 chain, while the β1 chain can be of either human or mouse origin, indicating strict specificity for the α5β1 heterodimer (Bukowski et al., 2009; DOI: 10.1007/978-1-59745-332-5). In clinical testing, weekly 15 mg/kg IV dosing achieved trough serum levels >150 µg/mL, with 2–3× accumulation by Day 50, detectable antibody in ascites, reduction in circulating endothelial progenitor cells, and a favorable safety profile. The use of this antibody in IHC-P was demostrated (Bell McGuinn et al., 2011; PMID: 21276608). Clone F200, a Fab derivative of M200, is available upon request.

Specifications

More Information
Brand	Vector Labs
UNSPSC	12161500

Reviews